View source for Biocon

{{Short description|Indian multinational biopharmaceutical company}}
{{multiple issues|
{{advert|date=April 2012}}
{{COI|date=May 2016}}
}}
{{Use Indian English|date=December 2020}}
{{Use dmy dates|date=September 2020}}
{{Infobox company
| name = Biocon Limited
| logo = Biocon Logo.svg
| image = Bangalore Biocon.jpg
| image_caption = Headquarters at [[Electronic City]], [[Bangalore]]
| type = [[Public company|Public]]
| traded_as = {{BSE|532523}} <br /> {{NSE|BIOCON}}
| founder = [[Kiran Mazumdar-Shaw]]
| key_people = {{ubl
|[[Kiran Mazumdar-Shaw]] (executive chairperson)
|Peter Bains (Group CEO)
|Siddharth Mittal (CEO & Managing Director)
|Shreehas P Tambe (CEO & Managing Director, Biocon Biologics Limited)
}}
| ISIN = {{ISIN|sl=n|pl=y|INE376G01013}}
| industry = {{ubl|[[Biopharmaceutical]]|[[Biotechnology]]}}
| products = {{ubl|[[Biologics]]|Small molecules|Branded formulations| Research services}}
| services = 
| revenue = {{Increase}} {{INRConvert|16470|c}} (2025)
| operating_income = {{Increase}} {{INRConvert|4374|c}} (2025)
| net_income = {{decrease}} {{INRConvert|1013|c}} (2025)
| assets = {{Increase}} {{INRConvert|58797|c}} (2025)
| equity = {{Increase}} {{INRConvert|27712|c}} (2025)
| num_employees = 16,545 <small>(March 2023)</small><ref name="biocon2017">{{cite web|url=http://www.biocon.com/docs/Biocon_Annual_Report_2017.pdf|title=Biocon Annual Report 2017|publisher=Biocon}}</ref>
| subsid = {{ubl|Biocon Biologics| Syngene International}}
| intl = 
| foundation = {{Start date and age|1978|p=y}}
| slogan = 
| location_city = [[Bengaluru]], [[Karnataka]]
| location_country = India
| homepage = {{URL|www.biocon.com}}
| footnotes = Financials {{as of|2025|03|31|lc=y|df=yes}}.<ref>{{cite web |title=Q4 & Full Year FY25 Earnings Presentation |url=https://www.biocon.com/docs/Q4&Full-Year-FY25-Earnings-Presentation.pdf |publisher=Biocon |access-date=15 May 2025}}</ref><ref>{{cite web |title=Audited financial results (standalone and consolidated) of the Company for the quarter and financial year ended March 31, 2025 |url=https://www.biocon.com/docs/OutcomeofBM08052025.pdf |publisher=Biocon |access-date=15 May 2025}}</ref>
}}

'''Biocon Limited''' is an Indian [[biopharmaceutical]] company based in [[Bengaluru]]. It was founded by [[Kiran Mazumdar-Shaw]] in 1978.<ref name="ref1" /> The company manufactures [[Generic drug|generic]] [[Active ingredient|active pharmaceutical ingredients]] (APIs) that are sold in approximately 120 countries,<ref>{{Cite web |title=Active Pharmaceutical Ingredient (API) |url=https://www.biocon.com/businesses/generics/api-overview/ |access-date=2022-12-26 |website=Biocon |date=3 July 2020 |language=en-US}}</ref> including the United States and Europe.<ref name="ref1" /> It also manufactures novel biologics as well as [[biosimilar insulins]] and [[Antibody|antibodies]], which are sold in India as branded formulations. Biocon's biosimilar products are also sold in both bulk and formulation forms in several emerging markets.<ref>{{cite journal | last1=Plum-Mörschel | first1=Leona | last2=Singh | first2=Gursharan | last3=Murugesan | first3=Sundara Moorthi Nainar | last4=Marwah | first4=Ashwani | last5=Panda | first5=Jayanti | last6=Loganathan | first6=Subramanian | last7=Athalye | first7=Sandeep N. | title=Pharmacokinetic and pharmacodynamic equivalence of Biocon's biosimilar Insulin-R with the US -licensed Humulin® R formulation in healthy subjects: Results from the RHINE -1 ( Recombinant Human INsulin Equivalence-1 ) study | journal=Diabetes, Obesity and Metabolism | volume=24 | issue=4 | date=2022 | issn=1462-8902 | pmid=34981621 | pmc=9303355 | doi=10.1111/dom.14635 | pages=713–721}}</ref>

Biocon's formulations for the Indian market include [[Metabolism|metabolics]], [[oncology]], [[immunotherapy]] and [[nephrology]] products. Some of Biocon's key brands in India include INSUGEN (rh-insulin), BASALOG ([[Insulin glargine|Glargine]]), BIOMAb EGFR ([[Nimotuzumab]]), BLISTO ([[Glimepiride]] + [[Metformin]]), CANMAb ([[Trastuzumab]]), Evertor ([[Everolimus]]), TACROGRAF ([[Tacrolimus]]), ALZUMAb ([[Itolizumab]]) and KRABEVA ([[Bevacizumab]]).<ref name="ref1" />

'''Syngene International Limited''' (Syngene) is a publicly listed subsidiary of Biocon, operating in the [[Contract manufacturing organization|contract research and development organization]].<ref name="ref1" />

==History==
Biocon was founded in 1978 with US$10,000 as the initial capital by a [[Kiran Mazumdar-Shaw|Kiran Mazumdar]] who was born to [[Gujarati people|Gujarati]] parents in [[Bangalore]].<ref>{{Cite web|last=Egan|first=Mary Ellen|title=Big Shot in Bangalore|url=https://www.forbes.com/forbes/2004/1018/088.html|access-date=2021-03-07|website=Forbes|language=en}}
</ref><ref>{{Cite web |last=Katyal |first=Surabhi |date=2015-06-15 |title=6 Indian and Indian Origin Women in the list of Forbes 100 Most Powerful Women in the World |url=https://thebetterindia.com/25233/six-indians-indian-origins-made-list-forbes-powerful-women-world/ |access-date=2024-09-21 |website=The Better India |language=en-US}}</ref>

In 1979, Biocon became the first Indian company to manufacture and export enzymes to the US and Europe.<ref>{{Cite web|url=http://www.indianmirror.com/indian-industries/top-industries/biocon.html|title=Biocon, India's largest biotech company.|last=nimmi|website=www.indianmirror.com|language=en-US|access-date=8 February 2018}}</ref>

In 1989, [[Unilever]] acquired Biocon Biochemicals Ltd. in Ireland and merged it with its subsidiary Quest International. Biocon received US funding for proprietary technologies.<ref name="ref8" />

In 1994, Biocon established Syngene International as a custom research company.<ref name="ref8" />

During 1998, Unilever agreed to sell its shareholding in Biocon to the Indian promoters. Biocon became an independent entity.<ref>{{Cite book|url=https://books.google.com/books?id=a9WGAwAAQBAJ&q=1998%E2%80%94Unilever+agrees+to+sell+its+shareholding+in+Biocon+to+the+Indian+promoters.+Biocon+becomes+an+independent+entity&pg=PA214|title=Winning Strategies for Business|last=Baisya|first=Rajat K.|date=9 September 2010|publisher=SAGE Publications India|isbn=9788132106081|language=en}}</ref>

In 2001, Biocon became the first Indian company to be approved by the [[Food and Drug Administration|USFDA]] for the manufacture of [[lovastatin]]; PlaFractor was granted a US 2001 and worldwide patent.<ref>{{Cite book|url=https://books.google.com/books?id=az8D9OOvfF0C&q=biocon+Becomes+the+first+Indian+company+to+be+approved+by+USFDA+for+the+manufacture+of+lovastatin&pg=PA654|title=Strategic Management 10E|last=Pearce|date=2009|publisher=McGraw-Hill Education (India) Pvt Limited|isbn=9780070264380|language=en}}</ref>

In 2003, Biocon became the first company worldwide to develop human insulin on a [[Pichia pastoris|pichia]] expression system.<ref>{{Cite web|url=https://www.brandindiapharma.in/pharmaceutical-companies-india/biocon-limited|title=Biocon Ltd: About Biocon Pharma Company Founder, CEO, Products & Contact Address|website=www.brandindiapharma.in|access-date=8 February 2018}}</ref>

In 2006, BIOMAb EGFR, the first indigenously developed humanised monoclonal antibody for head-and-neck cancer, was launched, and [[A. P. J. Abdul Kalam|APJ Abdul Kalam]] inaugurated India's largest biotech-hub, Biocon Park.<ref>{{Cite web|url=http://www.evaluategroup.com/Universal/View.aspx?type=Story&id=95300|title=Dr. APJ Abdul Kalam Dedicates India\'s First Cancer Drug BIOMab EGFR to the Nation and Inaugurates India\'s Largest Biotech-Hub "Biocon Park" {{!}} Evaluate|website=www.evaluategroup.com|access-date=8 February 2018}}</ref>

In 2008, Biocon acquired a 70% stake in German pharmaceutical company AxiCorp GmbH.<ref>{{Cite web|url=http://www.evaluategroup.com/Universal/View.aspx?type=Story&id=149061&sectionID=&isEPVantage=no|title=Biocon Acquires 70% Stake in German Pharmaceutical Company, AxiCorp: Biosimilars Will be Main Focus {{!}} Evaluate|website=www.evaluategroup.com|access-date=8 February 2018}}</ref>

During 2009, a Syngene-[[Bristol-Myers Squibb|Bristol Myers Squibb]] research facility was established in Bengaluru.<ref>{{Cite book|url=https://books.google.com/books?id=aoHRAwAAQBAJ&q=syngene+bms+partnership+2009&pg=PA451|title=India's Healthcare Industry: Innovation in Delivery, Financing, and Manufacturing|last=Burns|first=Lawton R.|date=13 January 2014|publisher=Cambridge University Press|isbn=9781107044371|language=en}}</ref>

Later in 2009, [[Mylan]] announced a strategic collaboration with Biocon to enter the global generic biologics market.<ref>{{Cite news|url=http://newsroom.mylan.com/press-releases?item=122588|title=Mylan Announces Strategic Collaboration with Biocon to Enter the Global Generic Biologics Market|work=MediaRoom|access-date=8 February 2018}}</ref>

In 2010, Biocon expanded to [[Malaysia]], with a biopharmaceutical manufacturing and R&D facility established in [[Iskandar Malaysia|Iskandar]], [[Johor]].<ref>{{Cite news|url=https://www.asianscientist.com/2011/09/pharma/biocon-limited-rnd-facility-bio-xcell-malaysia/|title=Biocon Limited To Build US$161 Million R&D Facility in Bio-XCell, Malaysia|date=11 September 2011|work=Asian Scientist Magazine {{!}} Science, technology and medical news updates from Asia|access-date=8 February 2018|language=en-US}}</ref>

In 2012, [[Abbott Laboratories|Abbott]] announced a collaboration with Syngene to open the first nutrition R&D center in India.<ref>{{Cite press release|url=https://www.prnewswire.com/news-releases/abbott-announces-collaboration-with-syngene-to-open-first-nutrition-rd-center-in-india-149948055.html|title=Abbott Announces Collaboration with Syngene to Open First Nutrition R&D Center in India|last=Abbott|website=prnewswire.com|language=en|access-date=8 February 2018}}</ref>

During 2013, Biocon launched the biologic drug ALZUMAb to treat [[psoriasis]].<ref>{{Cite news|url=http://www.thehindubusinessline.com/companies/Biocon-unveils-biologic-drug-to-treat-skin-disorder/article20647520.ece|title=Biocon unveils biologic drug to treat skin disorder|work=@businessline|access-date=8 February 2018|language=en}}</ref>

During 2014, Biocon launched the first biosimilar drug, CANMAb, to treat [[breast cancer]].<ref>{{cite web|url=http://timesofindia.indiatimes.com/business/india-business/Kiran-Mazumdar-Shaws-Biocon-develops-new-breast-cancer-drug/articleshow/29016754.cms |title=Kiran Mazumdar-Shaw's Biocon develops new breast cancer drug |work=[[The Times of India]] |date=18 January 2014 |access-date=19 January 2014}}</ref>

In 2015, Biocon launched a [[hepatitis-C]] drug in India under the brand name CIMIVIR-L.<ref>{{Cite news|url=http://www.livemint.com/Companies/78WwKeykyzx3G5X4AhcQKJ/Biocon-launches-hepatitisC-drug-in-India.html|title=Biocon launches hepatitis-C drug in India|last=Pilla|first=Viswanath|date=24 December 2015|work=livemint.com/|access-date=8 February 2018}}</ref>

In 2016, Biocon became the first Indian company to launch a [[biosimilar]] [[insulin glargine]] pen in Japan.<ref>{{Cite news|url=http://www.livemint.com/Companies/T3byt5dkq71gZoWez8fhRL/Biocons-partner-FUJIFILM-launches-insulin-glargine-in-Japan.html|title=Biocon's partner FUJIFILM launches insulin glargine in Japan|last=Pilla|first=Viswanath|date=15 July 2016|work=livemint.com/|access-date=20 December 2017}}</ref>

During 2016, Syngene set up an [[Amgen]] R&D center in Bangalore.<ref>{{Cite web|url=https://www.fiercebiotech.com/cro/indian-cro-syngene-sets-up-amgen-r-d-center-bangalore|title=Indian CRO Syngene sets up Amgen R&D center in Bangalore {{!}} FierceBiotech|website=www.fiercebiotech.com|date=6 September 2016 |language=en|access-date=8 February 2018}}</ref>

In 2017, Biocon's Insugen became the first locally manufactured biosimilar product to be approved for sale by the Malaysian drug regulator.<ref>{{Cite web|url=https://www.biosimilardevelopment.com/doc/biocon-wins-myr-million-contract-for-insulin-from-moh-malaysia-0001|title=Biocon Wins MYR 300 Million Contract For Insulin From MoH Malaysia|website=www.biosimilardevelopment.com|language=en|access-date=20 December 2017}}</ref>

In 2017, USFDA approved [[Mylan]]-Biocon's biosimilar for the cancer drug [[Trastuzumab|Herceptin]].<ref>{{Cite news|url=http://www.livemint.com/Industry/AdFKCQcZvRRXnToosfdMbO/US-FDA-approves-MylanBiocons-biosimilar-for-cancer-drug-He.html|title=US FDA approves Mylan-Biocon's biosimilar for cancer drug Herceptin|last=Trivedi|first=Isha|date=2 December 2017|work=livemint.com/|access-date=8 February 2018}}</ref>

During 2018, Biocon and Mylan received the European Commission's approval to market the biosimilar insulin glargine.<ref>{{cite news |title=Biocon, Mylan get European Commission approval to market biosimilar insulin glargine|url=https://business.medicaldialogues.in/biocon-mylan-get-european-commission-approval-market-biosimilar-insulin-glargine/ |publisher= Business Medical Dialogues|date=30 March 2018 }}</ref>

During 2021, Biocon Biologics and [[Serum Institute of India]] formed a joint agreement to commercialise vaccines, biological drugs, and antibody therapies together.<ref name=":1">{{Cite news |last=Das |first=Sohini |date=2021-09-17 |title=Biocon Biologics, Serum Institute Life Sciences enter strategic alliance |work=Business Standard India |url=https://www.business-standard.com/article/companies/biocon-biologics-serum-institute-life-sciences-enter-strategic-alliance-121091700898_1.html |access-date=2022-03-23}}</ref> Another aspect of the deal involved Bicocon selling 15% of its biologics subsidiary to the [[Serum Institute of India]], in return for Biocon gaining access to 100 million annual doses of vaccines for a 15-year period.<ref name=":1" />

During 2022, Biocon Biologics bought the [[biosimilar]] assets of [[Viatris]] for $3.34 billion.<ref>{{Cite web |last=Rajagopal |first=Divya |date=2022-03-01 |title=Biocon's unit buys biosimilar assets of Viatris for $3.34 billion |url=https://www.livemint.com/companies/biocons-unit-buys-biosimilar-assets-of-viatris-for-3-34-billion-11646075550724.html |access-date=2022-03-22 |website=mint |language=en}}</ref>

==Corporate governance==
[[File:STR 6036.jpg|thumb|Kiran Mazumdar-Shaw is an Indian entrepreneur. She founded Biocon in 1978.]]

Biocon's CMD [[Kiran Mazumdar-Shaw]] joined Biocon in 1978.<ref name="ref12"/><ref name="ref13"/><ref name="ref14"/> Her efforts in biotechnology have drawn global recognition both for the industry in India and for Biocon. She was called India's "biotech queen" by ''[[The Economist]]''<ref name="ref15"/> and India's "mother of invention" by ''[[The New York Times]]''.<ref name="ref16"/> She was named among ''[[Time (magazine)|Time]]'' magazine's 2010 100 most influential people in the world, not only due to her contribution to the biotech industry, but also because she gives back to the community.<ref name="ref17"/> Shaw has been featured on the ''[[Forbes]]'' list of "The World's 100 Most Powerful Women"<ref name="ref18"/> and in the ''[[Financial Times]]'' "Top 50 Women in Business" list.<ref name="ref19"/>

Shaw is the recipient of several awards including the [[Nikkei Asia Prize]], 2009 for Regional Growth,<ref name="ref21"/> Express Pharmaceutical Leadership Summit Award 2009 for Dynamic Entrepreneur, ''[[The Economic Times]]'' 'Businesswoman of the Year', the '[[Veuve Clicquot]] Initiative For Economic Development For Asia, [[Ernst & Young]]'s Entrepreneur of the Year Award for Life Sciences & Healthcare, 'Technology Pioneer' recognition by World Economic Forum and the Indian Chamber of Commerce Lifetime Achievement Award. She has received two Indian national awards, the [[Padma Shri]] (1989) and [[Padma Bhushan]] (2005), for her pioneering efforts in industrial biotechnology.<ref name="ref12"/>

Christiane Hamacher was appointed as the CEO of Biocon Biologic India Limited, with her term starting in March 2019.<ref>{{cite news|url=https://business.medicaldialogues.in/biocon-appoints-christiane-hamacher-as-ceo-of-biocon-biologics-india/|title=Biocon appoints Christiane Hamacher as CEO of Biocon Biologics India|date=2 March 2019|work=Medical Dialogues}}</ref>

On 3 December 2019, Siddharth Mittal took over from Arun Chandavarkar, who retired as [[Chief executive officer|CEO]] and joint managing director of Biocon.<ref>{{cite news|date=3 December 2019|title=Biocon names Siddharth Mittal as new CEO, Joint MD; bids farewell to Arun Chandavarkar|publisher=Medical Dialogues|url=https://business.medicaldialogues.in/biocon-names-siddharth-mittal-as-new-ceo-joint-md-bids-farewell-to-arun-chandavarkar/}}</ref>

In 2021, Hamacher resigned from her position, following differences with Kiran Mazumdar-Shaw.<ref>{{Cite web |last= |first= |date=2021-01-22 |title=Christiane Hamacher quits as CEO of Biocon Biologics |url=https://www.thehindubusinessline.com/companies/christiane-hamacher-quits-as-ceo-of-biocon-biologics/article33637778.ece |access-date=2024-09-21 |website=BusinessLine |language=en}}</ref>

==Subsidiaries==
=== Biocon Biologics ===
[[File:Biocon Park .jpg|thumb|Inside Biocon Research Centre in Biocon Park, [[Bommasandra]], [[Bangalore]]]]

Biocon Biologics is Biocon's biosimilar subsidiary. In 2021, Biocon and Viatris received approval to launch [[Insulin glargine|Semglee]], an insulin glargine-yfgn injection, the first interchangble biosimilar for [[diabetes]] in the United States.<ref>{{Cite web |date=2021 |title=Press Release titled "Biocon Biologics and Viatris Inc. Receive Historic Approval for First Interchangeable Biosimilar Semglee® (insulin glargine-yfgn injection) for the Treatment of Diabetes" |url=https://www.biocon.com/docs/PressRelease_USFDA_BBL_Biocon_29072021.pdf |access-date=22 March 2022 |website=Biocon.com}}</ref> In 2021, Biocon sold 15% of Biocon Biologics to [[Serum Institute of India]] for a valuation of $4.9 billion, for which Biocon will receive access to 100 million doses of vaccines per annum for 15 years.<ref name=":2">{{Cite web |last=Biocon |date=16 September 2021 |title=Biocon Biologics and Serum Institute Life Sciences Announce Strategic Alliance |url=https://www.biocon.com/biocon-biologics-and-serum-institute-life-sciences-announce-strategic-alliance/ |access-date=2022-04-23 |website=Biocon |language=en-US}}</ref> These vaccines will mainly be supplied from Serum Institute's upcoming vaccine facility in Pune, and Biocon will also have the commercialization rights of Serum Institute's vaccine portfolio, which includes the COVID-19 vaccine, for the international markets.<ref name=":2" /> In May 2022, Viatris sold its biosimilars division to Biocon Biologics for a price of US$3.335 billion.<ref>{{Cite web |last=Li |first=Robert |date=March 2, 2022 |title=Viatris sells biosimilars unit for USD 3.335 billion |url=https://iclg.com/ibr/articles/17681-viatris-sells-biosimilars-unit-for-usd-3-335-billion |access-date=March 31, 2022 |website=ICLG}}</ref>

===Syngene International Ltd===
Established in 1993, Syngene International Limited is a [[Contract manufacturing organization|contract research and development organization]] (CDMO). In the CDMO space, Syngene primarily focuses on research innovation and manufacturing services for their clients.<ref name=":0">{{Cite web |last=Babu |first=Venkatesha |date=2021 |title=We are co-innovating with global pharma companies: Syngene MD & CEO |url=https://www.thehindubusinessline.com/companies/we-are-co-innovating-with-global-pharma-companies-syngene-md-ceo/article38031492.ece |access-date=2022-03-15 |website=www.thehindubusinessline.com |language=en}}</ref> The company has four divisions: [[drug discovery]] services, dedicated research centres, development devices and manufacturing.<ref name=":0" /> Syngene works with eight of the top 10 global pharma companies and, Syngene's clients include Amgen, [[Zoetis]], [[GSK plc|GlaxoSmithKline]] and Bristol Myers Squibb.<ref>{{Cite web |last=Ghosh |first=Debojyoti |date=2021 |title=Syngene's winning formula |url=https://www.fortuneindia.com/enterprise/syngenes-winning-formula/105633 |access-date=2022-03-15 |website=www.fortuneindia.com |language=en}}</ref> Syngene has been expanding its operations. Since 2020, the company has opened an R&D centre in Hyderabad, is building an API manufacturing facility in [[Mangalore]], which was scheduled to be commissioned in 2022, and has expanded their R&D facility in Bangalore.<ref>{{Cite web |last=Rughani |first=Kushal |date=10 February 2021 |title=Initiating Coverage: Syngene International Ltd |url=https://www.hdfcsec.com/hsl.research.pdf/Initiating%20Coverage%20-%20Syngene%20International_10022021.pdf |access-date=22 April 2022 |website=HDFC Securities |page=2 }}</ref> Syngene also provides biologics CDMO services.<ref>{{Cite web |last1=Khandekar |first1=Siddhant |last2=Thakur |first2=Raunak |date=21 January 2022 |title=Syngene International (SYNINT) |url=https://www.icicidirect.com/mailimages/IDirect_Syngene_Q3FY22.pdf |access-date=17 May 2022 |website=ICICI Direct |page=2 }}</ref> In July 2022, Syngene signed a 10-year agreement with Zoetis to manufacture the drug substance for Librela (bedinvetmab), a [[First-in-class medication|first-in-class]] [[monoclonal antibody]] used for treating [[osteoarthritis]] in dogs.<ref>{{Cite web |last=Rautela |first=Isha |date=2022-07-14 |title=Syngene inks 10-year biologics manufacturing pact with Zoetis |url=https://www.thehindubusinessline.com/companies/syngene-inks-10-year-biologics-manufacturing-pact-with-zoetis/article65640179.ece |access-date=2022-07-17 |website=www.thehindubusinessline.com |language=en}}</ref> SynVent is Syngene's drug discovery and development platform for both [[Small molecule|small]] and [[Macromolecule|large molecules]].<ref>{{Cite web |title=SynVent Integrated Drug Discovery |url=https://www.syngeneintl.com/solutions/discovery/integrated-drug-discovery-solutions/ |access-date=24 July 2022 |website=Syngene International}}</ref> In September 2022, Biocon divested 5.4% of its shares in Syngene International.<ref>{{Cite web |last=Jaiswar |first=Pooja Sitaram |date=2022-09-06 |title=Biocon divests over ₹1,220 crore stake in Syngene International in bulk deal |url=https://www.livemint.com/market/stock-market-news/biocon-divests-over-rs-1-220-crore-stake-in-syngene-international-in-bulk-deal-should-you-buy-11662478237201.html |access-date=2022-09-08 |website=mint |language=en}}</ref>

==== Clinigene ====
Clinigene International Limited is a subsidiary of Syngene offering international pharmaceutical majors Phase I-IV clinical trials and studies for novel/generic molecules.<ref name="ref12"/>

===BBPL===
Biocon established Biocon Biopharmaceuticals Pvt. Ltd. (BBPL) in 2003 as a joint venture with the Cuban institute CIMAB to develop and market a range of MAbs and cancer vaccines.<ref name="ref12"/>

===Biocon-AxiCorp===
In 2008, Biocon acquired a majority stake of 70% in AxiCorp GmbH, a German pharmaceutical marketing company.<ref>{{Cite journal |date=2006-10-29 |title=Atlas Copco sells majority stake in rental business |url=http://dx.doi.org/10.1016/s1359-6128(06)71621-4 |journal=Pump Industry Analyst |volume=2006 |issue=10 |pages=12 |doi=10.1016/s1359-6128(06)71621-4 |issn=1359-6128|url-access=subscription }}</ref>

===NeoBiocon===
Incorporated in January 2008, NeoBiocon FZ LLC is a research and marketing pharmaceutical company based in [[Abu Dhabi]].<ref>{{Cite web |title=Building on a Foundation of IP |url=https://www.wipo.int/ipadvantage/en/details.jsp?id=2602 |access-date=2023-03-20 |website=www.wipo.int |language=en}}</ref>

===Biofusion Therapeutics Limited===
Biofusion Therapeutics Limited was incorporated in March 2021. It is 100% owned by Biocon.<ref>{{Cite web |title=Biocon incorporates wholly-owned subsidiary Biofusion Therapeutics |url=https://flipit.money/flips/biocon-incorporates-wholly-owned-subsidiary-biofusion-therapeutics |access-date=2023-03-20 |website=flipit.money |language=en}}</ref>

==Strategic partnerships==
===Biocon and Amylin===
In 2009, Biocon and [[Amylin Pharmaceuticals]] of the United States entered into an agreement to develop, commercialise and manufacture a novel peptide therapeutic for the potential treatment of diabetes. Amylin provides expertise in peptide hormone development, particularly in the area of phybrid technology and metabolic disease therapeutics. Biocon will utilise its expertise in recombinant microbial expression and experience in preclinical and clinical development of diabetes products to manufacture the compound.<ref name="ref12"/>

===Biocon and IATRICa===
In 2008, Biocon and IATRICa of the United States announced a strategic partnership to co-develop immunoconjugates for targeted immunotherapy of cancers and infectious diseases. The companies are co-developing candidate products based upon IATRICa's technology platform and Biocon's expertise in drug development, biologics manufacturing, and clinical research. The goal of this collaboration is to develop a therapeutic vaccine where the T cell-mediated immunity is enhanced and maintained against a tumor that otherwise evades immune responses. Methods of developing, characterising and scaling up of conjugated monoclonal antibody production are being currently studied.<ref name="ref12"/>

===Biocon and Viatris===
In 2009, Biocon signed a collaboration agreement with [[Viatris]] to develop and commercialize generic biologics. Viatris and Biocon will share development, capital, and other costs to bring products to market. Viatris will have exclusive commercialisation rights in the USA, Canada, Japan, Australia, New Zealand, EU, and European Free Trade Association countries through a profit-sharing arrangement with Biocon.<ref name="ref12"/>

===Biocon and Optimer===
Biocon and [[Optimer Pharmaceuticals|Optimer]] Pharmaceuticals, a biopharmaceutical company focused on the treatment of serious infections such as [[Clostridioides difficile infection]] (CDI), have entered into a long-term supply agreement for the commercial manufacturing of the active pharmaceutical ingredient, fidaxomicin.<ref name="ref1"/><ref name="ref12"/>

===Biocon and Vaccinex===
Biocon is also developing fully human antibodies BVX 10 and BVX-20 with a US antibody technology partner, Vaccinex. The partnership was initiated in 2004. BVX 10 targets TNF (Tumor Necrosis Factor) which is expressed at high levels in patients with rheumatoid arthritis. Biocon's strategic partnership with Vaccinex allows access to their proprietary human antibody platform technology, thereby providing a strong IP protection to Biocon's antibody pipeline.<ref name="ref1"/><ref name="ref12"/>

===Biocon and Abraxis===
In 2007, Biocon and [[Abraxis BioScience]], Inc. entered into an agreement that helped Biocon out-license the rights to develop and market a biosimilar version of [[GCSF]] (Granulocyte Colony-Stimulating Factor) to North American and European markets.<ref name="ref12"/>

=== Biocon and Sandoz ===
In January 2018, [[Sandoz]] (a [[Novartis]] division) announced a global partnership with Biocon to develop, manufacture, and commercialize multiple biosimilars in immunology and oncology for patients worldwide.<ref>{{Cite web|url=https://www.novartis.com/news/media-releases/sandoz-announces-exclusive-global-collaboration-biocon-next-generation-biosimilars|title=Sandoz announces exclusive global collaboration with Biocon on next-generation biosimilars {{!}} Novartis|website=Novartis|language=en|access-date=8 February 2018}}</ref>

==Operations==
Biocon's manufacturing facilities are located at two sites in [[Bangalore]].<ref name="ref12"/>

Biocon's [[R&D]] focuses on the entire drug development pathway – from process development to non-clinical and clinical research.<ref name="ref12"/>

Biocon offers 36 brands of products across the four therapeutic divisions of [[diabetes|diabetology]], [[nephrology]], [[oncology]], and [[cardiology]].<ref name="ref1"/>

==References==
{{Reflist|refs=

<!-- DO NOT remove comments, see WP:LDRHOW for more info-->

<ref name="ref1">{{Cite web |url=http://www.biocon.com/docs/AR10-BIOCON.pdf |title=Biocon Annual Report, 2010 |access-date=20 September 2010 |archive-url=https://web.archive.org/web/20101026031837/http://biocon.com/docs/AR10-BIOCON.pdf |archive-date=26 October 2010 |url-status=dead }}</ref>
<!--<ref name="ref2">Financial Express, Bangalore, 25 September 2009</ref>-->
<!--<ref name="ref5">[http://www.moneycontrol.com/news_html_files/news_attachment/2010/Biocon.pdf "Biocon Biopharmaceuticals becomes wholly owned subsidiary"], Moneycontrol.com, 6 April 2010</ref>-->
<!-- <ref name="ref6">Biotech Bonanza, India Today, 9 August 2004  (http://www.avesthagen.com/press/it.html)</ref> -->
<!-- not used <ref name="ref7">[http://www.hindu.com/mp/2010/04/27/bangindx.htm], The Hindu, Metro Plus, 27 April 2010 {{Webarchive|url=https://web.archive.org/web/20100502034816/http://www.hindu.com/mp/2010/04/27/bangindx.htm |date=2 May 2010 }}</ref>-->
<ref name="ref8">Kiran Mazumdar-Shaw, CMD, Biocon Ltd, [http://www.outlookmoney.com/article.aspx?88528 'Biotech Is Not for Punters'], Outlook Money, 15 July 2004</ref>
<!--<ref name="ref10">Economic Times, 18 September 2006</ref>-->
<!--<ref name="ref11">[http://www.technologyreview.in/biomedicine/23610/ "Biocon Injects Innovation Gene"] {{Webarchive|url=https://web.archive.org/web/20110717165453/http://www.technologyreview.in/biomedicine/23610/ |date=17 July 2011 }}, Technology Review, October 2009</ref>-->
<ref name="ref12">Biocon Website ({{cite web |url=http://biocon.com/ |title=Biocon - Biosimilars, Fermentation, Oral Insulin, Human Insulin, Immunosuppresants, Monoclonal Antibody, Recombinant Proteins, Biopharmaceutical, Biotechnology Company, EGFR, GCSF, Fermentation, Orlistat, Insulin Glargine, Insulin Lispro, Peptides, Insulin Aspart |access-date=3 August 2014 |url-status=dead |archive-url=https://web.archive.org/web/20140807042606/http://www.biocon.com/ |archive-date=7 August 2014 }})</ref>
<ref name="ref13">Nature Reviews Drug Discovery, July 2010</ref>
<ref name="ref14">Biospectrum India Friday, 11 July 2008</ref>
<ref name="ref15">Kiran Mazumdar Shaw, India's fermentation queen, 30 August 2001</ref>
<ref name="ref16">[https://www.nytimes.com/2003/08/16/world/the-saturday-profile-how-india-s-mother-of-invention-built-an-industry.html "How India's Mother of Invention Built an Industry"], 16 August 2003</ref>
<ref name="ref17">''Time'', 29 April 2010</ref>
<ref name="ref18">The World's 100 Most Powerful Women, Forbes, 19 August 2009</ref>
<ref name="ref19">''FT'' top 50 women in world business, ''Financial Times'', 25 September 2009</ref>
<!--<ref name="ref20">India's biotech future, Kiran Mazumdar-Shaw, ''The Hindu'', 15 August 2007</ref>-->
<ref name="ref21">The Hindu, 12 May 2009</ref>
<!-- <ref name="ref24">Data shows declining productivity in drug R&D, Reuters, 27 June 2010</ref> -->
<!-- <ref name="ref25">The Pharmerging Future, IMS Health, June 2009</ref> -->
<!-- <ref name="ref26">Biocon, IATRICa to co-develop drugs, ''Business Standard'', Bangalore, 17 January 2008</ref> -->
}}
{{Commons category|Biocon}}

{{Contract research organization}}
{{Nifty 200 companies}}
{{Bangalore topics}}
{{Authority control}}

[[Category:Biotechnology companies of India]]
[[Category:Pharmaceutical companies established in 1978]]
[[Category:Pharmaceutical companies of India]]
[[Category:Manufacturing companies based in Bengaluru]]
[[Category:Biotechnology companies established in 1978]]
[[Category:Indian companies established in 1978]]
[[Category:Indian brands]]
[[Category:1978 establishments in Karnataka]]
[[Category:Companies listed on the National Stock Exchange of India]]
[[Category:Companies listed on the Bombay Stock Exchange]]